Design and antitumor activity of programmed cell death ligand 1 epitope peptide vaccine

SHAO Shishuai; DUAN Shukang; TIAN Hong; YAO Wenbing; GAO Xiangdong

doi:10.11665/j.issn.1000-5048.2023022803

Journal of China Pharmaceutical University > 2023 > 54(2): 245-254. > DOI: 10.11665/j.issn.1000-5048.2023022803

SHAO Shishuai, DUAN Shukang, TIAN Hong, YAO Wenbing, GAO Xiangdong. Design and antitumor activity of programmed cell death ligand 1 epitope peptide vaccine[J]. Journal of China Pharmaceutical University, 2023, 54(2): 245-254. DOI: 10.11665/j.issn.1000-5048.2023022803

Citation:

PDF (1896 KB)

Design and antitumor activity of programmed cell death ligand 1 epitope peptide vaccine

Jiangsu Provincial Key Laboratory of Druggability of Biopharmaceuticals, School of Life Science and Technology, China Pharmaceutical University, Nanjing 211198, China

Funds: This study was supported by the National Natural Science Foundation of China (No.82073754, No.81973222); and the Key Research and Development Program of Xinjiang Uygur Autonomous Region (No.2020B03003)

More Information

Received Date: February 27, 2023
Revised Date: April 02, 2023

Graphical Abstract

Abstract

Abstract

Several programmed cell death protein 1 (PD-1) or its ligand (PD-L1) immune checkpoint blocking antibodies are available for clinical treatment, but only some patients show clinical response, so an alternative strategy for tumor immunotherapy is needed.A therapeutic tumor vaccine targeting PD-L1 is a meaningful attempt.In this study, we designed an epitope peptide vaccine targeting PD-L1, and then screened the immunogenic PD-L1 epitope peptide based on the humanized immune system (HIS) mouse model and further investigated its anti-tumor activity.The results show that the designed and screened PD-L1-B1 epitope peptide vaccine not only successfully induced PD-L1-specific humoral and cellular immunity, but also exhibit anti-tumor activity.In addition, immunotherapy increased T-lymphocyte infiltration of tumors and reshaped the tumor immunosuppressive microenvironment.In conclusion, PD-L1-B1 epitope peptide vaccine exhibits potent anti-tumor activity and may be an effective alternative immunotherapeutic strategy for patients insensitive to PD-1/PD-L1 blockade.
- tumor immunity,
- immune checkpoint,
- PD-L1,
- epitope peptide vaccine

FullText(HTML)

References (27)

References

[1]	Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade[J]. Cell, 2022, 185(3): 576.
[2]	Zhou F, Qiao M, Zhou CC. The cutting-edge progress of immune-checkpoint blockade in lung cancer[J]. Cell Mol Immunol, 2021, 18(2): 279-293.
[3]	André; T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 383(23): 2207-2218.
[4]	Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40.
[5]	Doroshow DB, Sanmamed MF, Hastings K, et al. Immunotherapy in non-small cell lung cancer: facts and hopes[J]. Clin Cancer Res, 2019, 25(15): 4592-4602.
[6]	Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance[J]. Nat Immunol, 2022, 23(5): 660-670.
[7]	Lei QY, Wang D, Sun K, et al. Resistance mechanisms of anti-PD-1/PD-L1 therapy in solid tumors[J]. Front Cell Dev Biol, 2020, 8: 672.
[8]	Tian H, Kang YL, Song XD, et al. PD-L1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD-1/PD-L1 pathway and activating PD-L1-specific immune responses[J]. Cancer Lett, 2020, 476: 170-182.
[9]	Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration[J]. Theranostics, 2021, 11(11): 5365-5386.
[10]	Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy[J]. Nat Rev Cancer, 2020, 20(11): 662-680.
[11]	McAuliffe J, Chan HF, Noblecourt L, et al. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy[J]. J Immunother Cancer, 2021, 9(9): e003218.
[12]	Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines[J]. Nat Rev Clin Oncol, 2021, 18(4): 215-229.
[13]	Ott PA, Hu-Lieskovan S, Chmielowski B, et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer[J]. Cell, 2020, 183(2): 347-362.e24.
[14]	Parkhurst MR, Robbins PF, Tran E, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers[J]. Cancer Discov, 2019, 9(8): 1022-1035.
[15]	Geuijen C, Tacken P, Wang LC, et al. A human CD137 × PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade[J]. Nat Commun, 2021, 12(1): 4445.
[16]	Munir S, Lundsager MT, J?rgensen MA, et al. Inflammation induced PD-L1-specific T cells[J]. Cell Stress, 2019, 3(10): 319-327.
[17]	Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PD-L1 in tumour immune evasion[J]. Nat Rev Immunol, 2020, 20(4): 209-215.
[18]	Guo LL, Overholser J, Good AJ, et al. Preclinical studies of a novel human PD-1 B-Cell peptide cancer vaccine PD-1-Vaxx from BALB/c mice to beagle dogs and to non-human primates (Cynomolgus monkeys)[J]. Front Oncol, 2022, 12: 826566.
[19]	Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018, 359(6382): 1350-1355.
[20]	Yu W, Jiang N, Ebert PJ, et al. Clonal deletion prunes but does not eliminate self-specific αβ CD8⁺ T lymphocytes[J]. Immunity, 2015, 42(5): 929-941.
[21]	Tian H, He Y, Song XD, et al. Nitrated T helper cell epitopes enhance the immunogenicity of HER2 vaccine and induce anti-tumor immunity[J]. Cancer Lett, 2018, 430: 79–87.
[22]	Su S, Zou ZY, Chen FJ, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer[J]. Oncoimmunology, 2017, 6(1): e1249558.
[23]	Nelde A, Rammensee HG, Walz JS. The peptide vaccine of the future[J]. Mol Cell Proteomics, 2021, 20: 100022.
[24]	Liao P, Wang WM, Wang WC, et al. CD8⁺ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4[J]. Cancer Cell, 2022, 40(4): 365-378.e6.
[25]	Gao Y, Yang JJ, Cai YX, et al. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling[J]. Int J Cancer, 2018, 143(4): 931-943.
[26]	Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy[J]. Nat Rev Immunol, 2018, 18(10): 648-659.
[27]	Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition[J]. Clin Cancer Res, 2016, 22(8): 1865-1874.

[1]	XIA Yuan, JIANG Qingling, WANG Xiaoting, LI Minjing, ZHENG Qiusheng, LI Defang. Norcantharidin induces apoptosis through autophagosome accumulation in breast cancer MDA-MB-231 cells[J]. Journal of China Pharmaceutical University, 2023, 54(6): 757-768. DOI: 10.11665/j.issn.1000-5048.2023033004
[2]	PAN Kemeng, CHEN Song, GAO Xiangdong, YAO Wenbing. Effects and mechanisms of microRNA-23b on neuronal apoptosis induced by Aβ_25-35[J]. Journal of China Pharmaceutical University, 2021, 52(4): 480-486. DOI: 10.11665/j.issn.1000-5048.20210411
[3]	WANG Yan, PING Fengfeng, ZHOU Danli, CHEN Yanhua, LING Jingjing. Masitinib alleviated cerebral ischemia/reperfusion injury by inhibiting autophagy and apoptosis[J]. Journal of China Pharmaceutical University, 2021, 52(2): 227-235. DOI: 10.11665/j.issn.1000-5048.20210212
[4]	LI Jing, LUO Fuling, WU Shengwang, WAN Jingyuan, ZHAO Hengguang. Hair regeneration in mice was promoted by 3-methyladenine through inhibiting autophagy flux[J]. Journal of China Pharmaceutical University, 2019, 50(4): 468-474. DOI: 10.11665/j.issn.1000-5048.20190412
[5]	WANG Jingjing, TIAN Chenguang, ZHANG Jinying, ZHANG Jijia, WU Zhaoke. Oroxylin A ameliorates isoproterenol-induced heart failure model in rats through promoting myocardial autophagy[J]. Journal of China Pharmaceutical University, 2018, 49(6): 731-738. DOI: 10.11665/j.issn.1000-5048.20180615
[6]	MA Jingfan, ZHANG Yan, YE Ganping, WEI Qiliang, QIU Longxin. Seneciphylline induced the autophagy of cervical cancer cells via MEK/ERK1/2 regulation[J]. Journal of China Pharmaceutical University, 2018, 49(5): 616-623. DOI: 10.11665/j.issn.1000-5048.20180515
[7]	YANG Rui, ZHU Yi, WANG Yin, MA Wenqi, WANG Xin, HAN Xiqiong, LIU Naifeng. Recent progress in autophagy and vascular calcification[J]. Journal of China Pharmaceutical University, 2018, 49(4): 401-406. DOI: 10.11665/j.issn.1000-5048.20180403
[8]	LIU Jing, HUANG Yanwei, ZHOU Bo, SONG Qingqing. Effect of R-(+)-lipoic acid on growth, proliferation and related mechanism in human HepG2 cells[J]. Journal of China Pharmaceutical University, 2017, 48(3): 348-354. DOI: 10.11665/j.issn.1000-5048.20170316
[9]	WANG Xue, ZHANG Pinghu. Advances in research on the modulation of autophagy by Ras/Raf/MEK/ERK signaling pathway[J]. Journal of China Pharmaceutical University, 2017, 48(1): 110-116. DOI: 10.11665/j.issn.1000-5048.20170117
[10]	ZHAO Hengguang, LUO Fuling. Rapamycin reverse lipopolysaccharide-induced acute lung injury through activating autophagy flux[J]. Journal of China Pharmaceutical University, 2015, 46(5): 605-609. DOI: 10.11665/j.issn.1000-5048.20150515

Cited By

Cited by

Periodical cited type(1)

阮浩澜，许姿敏，陈琪. 亚精胺的抗衰机制及在人体皮肤中的应用前景. 中国当代医药. 2023(35): 21-24 .

Other cited types(0)

Get Citation

PDF

XML

Article views (193) PDF downloads (374) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Design and antitumor activity of programmed cell death ligand 1 epitope peptide vaccine

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Design and antitumor activity of programmed cell death ligand 1 epitope peptide vaccine

Abstract

References

Related Articles

Cited by

Periodical cited type(1)

Other cited types(0)

Catalog

Export File

Citation

Format

Content